ARDELYX, INC.
Small-molecule therapeutics for kidney and cardiovascular diseases
- Sector
- Biotech
- Headquarters
- FREMONT, CA
- Founded
- 2007
- Latest Form D
- $110M, Aug 2016
- Total capital
- $210M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $210M
- 4 Form D · last Aug 2016
- 123 months since last filing
- Federal contracts
- $72K
- 12 awards · Veterans Affairs
- Rank in Biotech#344 of 4373
- Granted patents
- 22
- 18 pending · first 2018
- Rank in peer group#47 of 1449
Capital timeline
Latest events
- Federal contractVeterans Affairs · Xphozah 30 Mg$12K
- Federal contractVeterans Affairs · Xphozah 30 Mg$2K
- Federal contractVeterans Affairs · Xphozah 20 Mg$4K
- Federal contractVeterans Affairs · Xphozah 30 Mg$2K
- Federal contractVeterans Affairs · Xphozah 30 Mg$12K
- Federal contractVeterans Affairs · Xphozah 30 Mg$2K
- Federal contractVeterans Affairs · Xphozah$2K
- Private capital raisedForm D · SEC · 4th filing$110M
- Private capital raisedForm D · SEC · 3rd filing$77.8M
- Private capital raisedForm D · SEC · 2nd filing$17.6M
- Private capital raisedForm D · SEC · 1st filing$5M
Show 5 earlier federal awards
- Federal contractVeterans Affairs · Xphozah 30 Mg$2K
- Federal contractVeterans Affairs · Xphozah$16K
- Federal contractVeterans Affairs · Xphozah 30MG Tabs$6K
- Federal contractVeterans Affairs · Emerg. Xphozah [tenapanor] For The Boro Vamc Pharm 37129$6K
- Federal contractVeterans Affairs · Emerg. Xphozah [tenapanor] For The Boro Vamc Pharm 37129$6K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#47 · top 3%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Dominique CharmotResearcherExecutive Officer, DirectorLinked by 1 patent
- Annalisa JenkinsDirectorNamed in SEC Form D filings
- David CollierDirectorNamed in SEC Form D filings
- David MottDirectorNamed in SEC Form D filings
- David RosenbaumExecutive OfficerNamed in SEC Form D filings
- Elizabeth G. GrammerExecutive OfficerNamed in SEC Form D filings
Show all 17 people
- Gordon RingoldDirectorNamed in SEC Form D filings
- Jean FrechetDirectorNamed in SEC Form D filings
- Jeff JacobsExecutive OfficerNamed in SEC Form D filings
- Jeremy CaldwellExecutive OfficerNamed in SEC Form D filings
- Mark G. KaufmannExecutive OfficerNamed in SEC Form D filings
- Michael RaabExecutive Officer, DirectorNamed in SEC Form D filings
- Paul KornerExecutive OfficerNamed in SEC Form D filings
- Peter G. SchultzDirectorNamed in SEC Form D filings
- Richard RodgersDirectorNamed in SEC Form D filings
- Robert BazemoreDirectorNamed in SEC Form D filings
- William Bertrand, Jr.DirectorNamed in SEC Form D filings
What it has protected
USPTO · 22 granted of 40- PendingOral Formulation Of A Therapeutic CompoundUSPTOApplication 19462617
- PendingCompounds And Methods For Inhibiting Nhe-mediated Antiport In The Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract DisordersUSPTOApplication 19246080
- PendingCompounds Useful For Treating Gastrointestinal Tract DisordersUSPTOApplication 19070289
Show all 40 patent records
- Oral Formulation Of A Therapeutic CompoundJun 11, 2026 · Application 19462617Pending
- Compounds And Methods For Inhibiting Nhe-mediated Antiport In The Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract DisordersDec 4, 2025 · Application 19246080Pending
- Compounds Useful For Treating Gastrointestinal Tract DisordersAug 21, 2025 · Application 19070289Pending
- Compounds Useful For Treating Gastrointestinal Tract DisordersApr 22, 2025 · US 12,281,103Granted
- Hormone Receptor Modulators For Treating Metabolic Conditions And DisordersApr 10, 2025 · Application 18977676Pending
- Substituted 4-PHENYL Pyridine Compounds As Non-systemic TGR5 AgonistsFeb 27, 2025 · Application 18776075Pending
- Compounds And Methods For Treating HyperkalemiaFeb 27, 2025 · Application 18823388Pending
- Hormone Receptor Modulators For Treating Metabolic Conditions And DisordersJan 28, 2025 · US 12,209,088Granted
- Compounds And Methods For Inhibiting Nhe-mediated Antiport In The Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract DisordersNov 7, 2024 · Application 18749311Pending
- NHE3-BINDING Compounds And Methods For Inhibiting Phosphate TransportNov 7, 2024 · Application 18662929Pending
- Compounds And Methods For Inhibiting Phosphate TransportOct 3, 2024 · Application 18381799Pending
- Substituted 4-PHENYL Pyridine Compounds As Non-systemic TGR5 AgonistsSep 10, 2024 · US 12,084,472Granted
- Compounds And Methods For Treating HyperkalemiaJun 27, 2024 · Application 18518267Pending
- Compounds And Methods For Inhibiting Nhe-mediated Antiport In The Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract DisordersJun 25, 2024 · US 12,016,856Granted
- Glycyrrhetinic Acid Derivatives For Use In Treating HyperkalemiaJan 2, 2024 · US 11,858,959Granted
- Compounds And Methods For Inhibiting Phosphate TransportNov 14, 2023 · US 11,813,304Granted
- Intestinal Epithelial Cell CulturesOct 5, 2023 · Application 18132215Pending
- Glycyrrhetinic Acid Derivatives For Treating HyperkalemiaSep 26, 2023 · US 11,768,319Granted
- Hormone Receptor Modulators For Treating Metabolic Mutagenic And Fibrotic Conditions And DisordersSep 12, 2023 · US 11,753,410Granted
- Methods For Inhibiting Phosphate TransportSep 7, 2023 · Application 17986739Pending
- Glycyrrhetinic Acid Derivatives For Treating HyperkalemiaAug 31, 2023 · Application 18101009Pending
- Isoxazolyl-carbonyloxy AZABICYCLO[3.2.1]OCTANYL Compounds As Fxr ActivatorsAug 8, 2023 · US 11,718,619Granted
- Compounds Useful For Treating Gastrointestinal Tract DisordersSep 29, 2022 · Application 17558227Pending
- Compounds And Methods For Inhibiting Nhe-mediated Antiport In The Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract DisordersMay 3, 2022 · US 11,318,129Granted
- Compounds Useful For Treating Gastrointestinal Tract DisordersFeb 8, 2022 · US 11,242,337Granted
- Inhibitors Of Nhe-mediated AntiportOct 19, 2021 · US 11,147,884Granted
- Isoxazolyl-carbonyloxy AZABICYCLO[3.2.1]OCTANYL Compounds As Fxr ActivatorsAug 17, 2021 · US 11,091,482Granted
- NHE3-BINDING Compounds And Methods For Inhibiting Phosphate TransportJun 24, 2021 · Application 17138604Pending
- Substituted 4-PHENYL Pyridine Compounds As Non-systemic TGR5 AgonistsApr 6, 2021 · US 10,968,246Granted
- NHE3-BINDING Compounds And Methods For Inhibiting Phosphate TransportMar 9, 2021 · US 10,940,146Granted
- Hormone Receptor Modulators For Treating Metabolic Conditions And DisordersJan 21, 2021 · Application 16990827Pending
- Methods For Inhibiting Phosphate TransportNov 26, 2020 · Application 16880836Pending
- Hormone Receptor Modulators For Treating Metabolic Conditions And DisordersOct 6, 2020 · US 10,793,568Granted
- Compounds And Methods For Inhibiting Nhe-mediated Antiport In The Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract DisordersJan 28, 2020 · US 10,543,207Granted
- Compounds And Methods For Inhibiting Nhe-mediated Antiport In The Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract DisordersDec 12, 2019 · Application 16476838Pending
- Substituted 4-PHENYL Pyridine Compounds As Non-systemic TGR5 AgonistsAug 27, 2019 · US 10,392,413Granted
- Compounds And Methods For Inhibiting Nhe-mediated Antiport In The Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract DisordersAug 20, 2019 · US 10,385,024Granted
- Compounds And Methods For Inhibiting Nhe-mediated Antiport In The Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract DisordersAug 13, 2019 · US 10,376,481Granted
- NHE3-BINDING Compounds And Methods For Inhibiting Phosphate TransportApr 30, 2019 · US 10,272,079Granted
- Compositions And Methods For Treating HyperkalemiaMar 20, 2018 · US 9,919,006Granted
Related companies, and why
- ORA BIOMEDICAL, INC.Similar federal contract value in Biotech · $75K in contracts
- Agios PharmaceuticalsSimilar federal contract value in Biotech · $73K in contracts
- BIOLYTIC LAB PERFORMANCE, INC.Similar federal contract value in Biotech · $72K in contracts
- ATELERIX LIFE SCIENCES INCSimilar federal contract value in Biotech · $68K in contracts
- Abpro CorpSimilar federal contract value in Biotech · $66K in contracts
- RETROTHERAPY, LLCSimilar federal contract value in Biotech · $65K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .